- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06472674
China Healthy Aging Cohort Study (China-Ageing)
June 23, 2024 updated by: Xuanwu Hospital, Beijing
This is a community-based prospective cohort study in China.
The study has been initialized in 2024 and included older residents.
The goal of this observational study is to explore the risk factors related to disability and dementia in the elderly Chinese community population, and develop a risk prediction model for disability and dementia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a community-based prospective cohort study in China.
Individuals who were aged 60 years or older, had lived in the communities for more than 1 year, and had signed the informed consent form were enrolled in the present study.
The study has been initiated in 2024 and aimed to explore the risk factors related to disability and dementia in the elderly Chinese population, and develop a risk prediction model for disability and dementia.
This work consists of three steps as follows.
First, by integrating the data of the elderly cohort of 4 communities in Beijing, Shenzhen, Haikou and Hangzhou, we plan to establish a Chinese elderly database.
Second, to explore the risk factors of disability and dementia in elderly Chinese.
Third, to construct risk prediction models of disability and dementia in Chinese elderly.
Study Type
Observational
Enrollment (Estimated)
6780
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yi Tang, MD., PhD
- Phone Number: 00861083199456
- Email: tangyi@xwhosp.org
Study Locations
-
-
-
Beijing, China, 100053
- Recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Yi Tang, M.D., Ph.D.
- Phone Number: 00861083199456
- Email: tangyi@xwhosp.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Community residents aged 60 years or older in China
Description
Inclusion Criteria:
- Aged 60 years or older
- Lived in the community for more than 1 year
- Signed the informed consent form
Exclusion Criteria:
- Cannot complete the survey
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Total
All subjects
|
No intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The prevalence and incidence of functional disability using a population-based survey
Time Frame: An average of 1 to 2 years
|
Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder(Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
|
An average of 1 to 2 years
|
|
The prevalence and incidence of mild cognitive impairment using a population-based survey
Time Frame: An average of 1 to 2 years
|
Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.
|
An average of 1 to 2 years
|
|
The prevalence and incidence of dementia using a population-based survey
Time Frame: An average of 1 to 2 years
|
Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale.
The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.
|
An average of 1 to 2 years
|
|
The conversion rate of normal to mild cognitive impairment
Time Frame: An average of 1 to 2 years
|
Percentage of enrolled population that convert from normal to mild cognitive impairment
|
An average of 1 to 2 years
|
|
The conversion rate of mild cognitive impairment to dementia
Time Frame: An average of 1 to 2 years
|
Percentage of enrolled population that convert from mild cognitive impairment to dementia
|
An average of 1 to 2 years
|
|
The prevalence and incidence of movement disorder using a population-based survey
Time Frame: An average of 1 to 2 years
|
Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
|
An average of 1 to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yi Tang, MD., PhD, Xuanwu Hospital, Beijing
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2024
Primary Completion (Estimated)
June 1, 2063
Study Completion (Estimated)
June 1, 2063
Study Registration Dates
First Submitted
June 17, 2024
First Submitted That Met QC Criteria
June 23, 2024
First Posted (Actual)
June 25, 2024
Study Record Updates
Last Update Posted (Actual)
June 25, 2024
Last Update Submitted That Met QC Criteria
June 23, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024214001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Death
-
Amasya UniversityHealth Institutes of TurkeyCompleted
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSudden Infant Death SyndromeUnited States
-
Weill Medical College of Cornell UniversityEmpatica, Inc.Terminated
-
Harvard School of Public Health (HSPH)Population Services International; Community Empowerment LabCompletedPerinatal Death | Stillbirth | Neonatal DeathIndia
-
Children's Hospital Medical Center, CincinnatiEvery Child Succeeds; de Cavel Family SIDS FoundationCompletedSudden Infant Death Syndrome (SIDS)United States
-
CHU de ReimsCompletedSudden Death in ChildrenFrance
-
Lehigh Valley HospitalCompletedPrevention of Sudden DeathUnited States
-
Nantes University HospitalTerminatedExtra-hospital Sudden DeathFrance
-
Rachel Moon, MDCompletedSudden Infant Death SyndromeUnited States
-
National Center for Research Resources (NCRR)CompletedSudden Infant Death Syndrome
Clinical Trials on No intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted